Este IPO no ha sido traducido a su idioma todavía — mostrando la versión en inglés. [en]
TenNor Therap-B logo

TenNor Therap-B

06872 · HKEX
Listed

Dano Pharmaceutical is a biotechnology company approaching the commercialization stage, focusing on the discovery, development and commercialization of differentiated innovative pharmaceutical product…

Listed

IPO Timeline

  1. AbiertoMay 14
  2. CerrarMay 19
  3. SuscripciónMay 21
  4. PagoMay 22
  5. ListaMay 22

Principales hechos

Precio del número

HKD 75.70

Min Entry Fee

HKD 3,823.17

Acciones publicadas

8.86M

Tamaño del lote

50

Total Raise

HKD 670.4M

Estimación de la capacidad de mercado

HKD 3.92B

Asignación pública

10.0%

International Placement

90.0%

Panorama general de las empresas

Dano Pharmaceutical is a biotechnology company approaching the commercialization stage, focusing on the discovery, development and commercialization of differentiated innovative pharmaceutical products to address unmet clinical needs in the fields of bacterial infections and bacterial metabolism‑related diseases.

Uso de Proceeds

1、71.0% or approximately HK$395.7 million will be used for the research, development, registration filing and commercialisation of the Company’s core products;

2、7.0% or approximately HK$39.2 million will be used to fund the research and development of the oral formulation of TNP‑2092;

3、7.3% or approximately HK$40.9 million will be used for the research and development of other candidate products of the Company;

4、7.2% or approximately HK$40.2 million will be used for the construction of the Company’s own manufacturing plant;

5、7.5% or approximately HK$41.8 million will be used as working capital and for other general corporate purposes.

Patrocinio del registro de seguimiento

Se están renovando los datos de registro de pistas.

Intermediarios " Documentos "

Patrocinadores

  • 中信證券(香港)有限公司
  • 農銀國際融資有限公司

Underwriters

  • 中信里昂證券有限公司
  • 農銀國際證券有限公司
  • 華興證券(香港)有限公司
  • 富途證券國際(香港)有限公司
  • 老虎證券(香港)環球有限公司

Prospectus PDF

Prospectus PDF →

Cornerstone Investors

  • AMR Action Fund, L.P.
  • 华圆管理咨询(香港)有限公司
  • AMR Action Fund, SCSp
  • 东方资产管理(香港)有限公司
  • 骏升环球有限公司

Total

0

37.3% of placement

BBX no participa en el proceso de asignación para cualquier IPO enumerado en esta página. Esta página es sólo para fines informativos y no es asesoramiento de inversión.